Background
==========

Interleukin-33 (IL-33) is a novel cytokine that triggers inflammatory immune responses, but evidence of its role in human asthma, a common allergic airway disease, is lacking. There is also a paucity of information regarding which cells express IL-33, and what conditions promote its expression. We sought to investigate whether IL-33 is expressed in the lung tissue from patients with asthma.

Methods
=======

We obtained lung biopsy tissue specimens from asthmatic adults and from healthy control subjects, along with normal primary cells from human airways that were cultured *in vitro*. We studied expression of IL-33 in lung tissue specimens, and determined whether conditions seen in asthma promote IL-33 expression *in vitro*. We also assessed whether IL-33 expression is sensitive to glucocorticoid treatment.

Results
=======

Higher expression of IL-33 is detected in lung tissue from asthmatic patients compared to control subjects. IL-33 expression correlates TNF-α e.g. a hallmark of inflammation. Airway epithelium, smooth muscle cells and endothelium are all sources of IL-33. When exposed to inflammatory conditions, *in vitro* cultured bronchial smooth muscle and epithelial cells increased their IL-33 expression, which surprisingly remained intracellular. Finally, glucocorticoid did not significantly reduce TNF-α-induced IL-33 expression.

Conclusions
===========

Our study first describes IL-33 expression in asthma; it is increased in the lungs from asthmatics, and is enhanced under asthma-like *in vitro* conditions. IL-33 originates from structural cells of the airways and its expression does not respond to classic anti-inflammatory drug, thus reinforcing its relevance as a potential therapeutic target to treat asthma.
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